[EN] EBNA1 INHIBITORS AND THEIR METHOD OF USE<br/>[FR] INHIBITEURS D'EBNA1 ET LEUR PROCÉDÉ D'UTILISATION
申请人:WISAR INST OF ANATOMY AND BIOLOGY
公开号:WO2015073864A1
公开(公告)日:2015-05-21
Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
Sequential C–S and S–N Coupling Approach to Sulfonamides
A one-potthree-componentreaction involving nitroarenes, (hetero)arylboronic acids, and potassium pyrosulfite leading to sulfonamides was described. A broad range of sulfonamides bearing different reactive functional groups were obtained in good to excellent yields through sequential C-S and S-N coupling that does not require metal catalysts.